rac-(4,7,10-triscarboxymethyl-2-methyl-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid | 119928-85-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: rac-(4,7,10-triscarboxymethyl-2-methyl-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid
• 英文别名: MDOTA；2-methyl-1,4,7,10-tetraazacyclododecan-1,4,7,10-tetraacetic acid；2-methyl-1,4,7,10-tetraazacyclododecane-N,N',N",N'"-tetraacetic acid；1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, 2-methyl-；2-[4,7,10-tris(carboxymethyl)-6-methyl-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
• CAS: 119928-85-7
• 化学式: C₁₇H₃₀N₄O₈
• 分子量: 418.447
• InChiKey: HSXRCEVTMOWCFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -10.2
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  162
• 氢给体数：
  4
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  rac-(4,7,10-triscarboxymethyl-2-methyl-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 、 ytterbium hydroxide 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 rac-(4,7,10-tris-carboxymethyl-2,5,8,11-2-methyl-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid Yb(3+) complex
  参考文献：
  名称：

  聚甲基化的DOTA配体。2.刚性化镧系元素螯合物的合成以及烷基取代对构象迁移率和弛豫性的影响的研究。

  摘要：

  M4DOTA，[（（2S，5S，8S，11S）-4,7,10-三羧甲基-2,5,8,11-四甲基-1,4,7,10-四氮杂环十二烷-1-基]乙酸（ 2e）和M4DOTMA，（R）-2-[（2S，5S，8S，11S）-4,7,10-tris-（（（R）-1-羧乙基）-2,5,8,11-四甲基-1,4,7,10-四氮杂环十二烷-1-基]丙酸（3e）是配体DOTA（1e）的衍生物，形成空间拥挤的镧系元素螯合物。M4DOTMA形成高度对称且完全刚性的单个Y（3+）和Yb（3+）物种，其中环取代基在正方形反棱角排列中占据角位置，如分子力学计算和对M4DOTMA相对大小的定量解释所示偶极起源的顺磁性（1）H NMR位移。YbM4DOTMA（-）的NMR光谱显示0-10 ppm范围之外的两个强烈的甲基峰，其位移差异与温度密切相关。YbM4DOTMA（-）（3d）在磁共振测温成像中可能是有用的探针。四氮杂

  DOI：

  10.1021/ic025695e

文献信息

• COMPOUNDS FOR THE DIAGNOSIS OF DISEASES ASSOCIATED WITH VCAM EXPRESSION
  申请人：Port Marc

  公开号：US20110200533A1

  公开（公告）日：2011-08-18

  The present invention relates to a compound of the following general formula (I): Signal-Linker-Peptide (I) in which: -Signal represents a signal entity; -Linker, which may or may not be present, represents a chemical bond, and -Peptide represents a peptide comprising a VCAM-targeting peptide, the VCAM-targeting peptide being chosen from the peptides of formula below and the functional equivalents thereof: a) X1-X2-X3-X4-X5-X6-X7-X8-X9 (1) (SEQ ID No. 1) where X1 is absent or chosen from cysteine and methionine; X2 chosen from asparagine and glutamine; X3 chosen from asparagine and glutamine; X4 chosen from serine and threonine; X5 chosen from lysine, arginine, histidine and ornithine; X6 chosen from serine and threonine; X7 chosen from histidine, arginine and lysine; X8 chosen from threonine and serine; X9 is absent or chosen from cysteine and methionine; preferably, the peptide CNNSKSHTC (SEQ ID No. 2) and the peptide NNSKSHT (SEQ ID No. 3); b) X10-X11-X12-X13-X14-X15-X16-X17-X18 (2) (SEQ ID No. 4) with X10 chosen from cysteine and methionine; X11 chosen from methionine and cysteine; X12 chosen from lysine, arginine and alanine; X13 chosen from threonine and serine; X14 chosen from aspartic acid and glutamic acid; X15 chosen from threonine and serine; X16 chosen from arginine, alanine and lysine; X17 chosen from leucine, isoleucine and valine; X18 chosen from cysteine and methionine; preferably, the peptide CMKTDTRLC (SEQ ID No. 5); and the pharmaceutically acceptable salts of these compounds of a) or of b).

  本发明涉及以下一般式(I)的化合物：Signal-Linker-Peptide (I)其中：- Signal代表信号实体；- Linker，可以存在也可以不存在，代表化学键；- Peptide代表包含VCAM靶向肽的肽，所述VCAM靶向肽从以下式的肽中选择，以及其功能等效物：a) X1-X2-X3-X4-X5-X6-X7-X8-X9 (1) (序列号1)，其中X1不存在或从半胱氨酸和蛋氨酸中选择；X2从天冬氨酸和谷氨酸中选择；X3从天冬氨酸和谷氨酸中选择；X4从丝氨酸和苏氨酸中选择；X5从赖氨酸、精氨酸、组氨酸和鸟氨酸中选择；X6从丝氨酸和苏氨酸中选择；X7从组氨酸、精氨酸和赖氨酸中选择；X8从苏氨酸和丝氨酸中选择；X9不存在或从半胱氨酸和蛋氨酸中选择；优选的肽为CNNSKSHTC (序列号2)和NNSKSHT (序列号3)；b) X10-X11-X12-X13-X14-X15-X16-X17-X18 (2) (序列号4)，其中X10从半胱氨酸和蛋氨酸中选择；X11从蛋氨酸和半胱氨酸中选择；X12从赖氨酸、精氨酸和丙氨酸中选择；X13从苏氨酸和丝氨酸中选择；X14从天冬氨酸和谷氨酸中选择；X15从苏氨酸和丝氨酸中选择；X16从精氨酸、丙氨酸和赖氨酸中选择；X17从亮氨酸、异亮氨酸和缬氨酸中选择；X18从半胱氨酸和蛋氨酸中选择；优选的肽为CMKTDTRLC (序列号5)；以及a)或b)中的这些化合物的药用盐。
• New agents for magnetic imaging method
  申请人：Bracco Imaging S.p.A.

  公开号：EP1369134A1

  公开（公告）日：2003-12-10

  The invention provides MRI detectable species of formula (I)         Dp-Sn-Nm     (I) wherein D is a MRI detectable moiety    S is a spacer    N is a molecule of a nutrient or pseudo-nutrient    n is 0 or an integer    m is an integer and    p is an integer. These compounds are useful for internalising into tumor cells an amount of the MRI detectable moiety that is distinguishably higher than the amount internalised in normal healthy cells thus allowing the diagnosis of tumors. Preferred compounds of formula (I) are those wherein D is the chelated complex of a paramagnetic metal ion. In this case when the paramagnetic metal ion is a neutron capture isotope, e.g. 157Gd, the new compounds can also be used for the treatment of the tumor, by selective irradiation of the tumor mass.

  该发明提供了一种具有以下式（I）的MRI可检测物种： Dp-Sn-Nm（I） 其中D是MRI可检测的基团 S是一个间隔物 N是一种营养物质或伪营养物质的分子 n为0或整数 m为整数 p为整数 这些化合物对于将MRI可检测的基团内化到肿瘤细胞中的数量高于内化到正常健康细胞中的数量是有用的，从而实现肿瘤的诊断。首选的式（I）化合物是D为顺磁金属离子的螯合络合物。在这种情况下，当顺磁金属离子是中子俘获同位素时，例如157Gd，这些新化合物也可以用于通过选择性照射肿瘤组织来治疗肿瘤。
• COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS
  申请人：Port Marc

  公开号：US20100143250A1

  公开（公告）日：2010-06-10

  The present invention relates to a compound of general formula (I) below: Signal−Linker−Peptide (I) in which Signal represents a signal entity; Linker, which may or may not be present, represents a chemical bond and Peptide represents a peptide comprising an apoptosis-targeting peptide, the apoptosis-targeting peptide being chosen from the peptides having the formula below and the functional equivalents thereof: X1-X2-X3-X4-X5-X6 (1) (SEQ ID No 1) in which X1 and X2 represent, independently of one another, leucine or isoleucine, X3 and X4 represent lysine, X5 represents proline and X6 represents phenylalanine, advantageously the peptide L-I-K-K-P-F (SEQ ID No 11) and the functional equivalents thereof; D-A-H-S-X7-S (2) (SEQ ID No 2) in which X7 represents phenylalanine or leucine; P-G-D-L-X8-X9 (3) (SEQ ID No 3) in which X8 represents serine or valine and X9 represents threonine or arginine; H-G-X10-L-S-X11 (4) (SEQ ID No 4) in which X10 represents aspartic acid or histidine, and X11 represents threonine or isoleucine; V-L-G-E-R-G (5) (SEQ ID No 5); and the pharmaceutically acceptable salts of these compounds.

  本发明涉及一种通式（I）化合物：Signal−Linker−Peptide（I），其中Signal代表信号实体；Linker代表可能存在或不存在的化学键；Peptide代表包含凋亡靶向肽的肽，所述凋亡靶向肽选择以下具有通式的肽及其功能等效物：X1-X2-X3-X4-X5-X6（1）（SEQ ID No 1），其中X1和X2分别独立地表示亮氨酸或异亮氨酸，X3和X4表示赖氨酸，X5表示脯氨酸，X6表示苯丙氨酸，优选的肽为L-I-K-K-P-F（SEQ ID No 11）及其功能等效物；D-A-H-S-X7-S（2）（SEQ ID No 2），其中X7表示苯丙氨酸或亮氨酸；P-G-D-L-X8-X9（3）（SEQ ID No 3），其中X8表示丝氨酸或缬氨酸，X9表示苏氨酸或精氨酸；H-G-X10-L-S-X11（4）（SEQ ID No 4），其中X10表示天冬氨酸或组氨酸，X11表示苏氨酸或异亮氨酸；V-L-G-E-R-G（5）（SEQ ID No 5）；以及这些化合物的药学上可接受的盐。
• Diagnostic compounds for targeting a chemokine receptors
  申请人：Port Marc

  公开号：US20090202435A1

  公开（公告）日：2009-08-13

  The present invention relates to a compound comprising, firstly a component for targeting at least one chemokine receptor and, secondly, a detection component capable of being identified by a medical imaging method.

  本发明涉及一种化合物，包括第一部分用于靶向至少一种趋化因子受体的组分和第二部分是一种检测组分，能够通过医学成像方法被鉴定。
• MULTIMERIC MAGNETIC RESONANCE CONTRAST AGENTS
  申请人：Axelsson Oskar

  公开号：US20090238768A1

  公开（公告）日：2009-09-24

  The present invention relates to novel compounds of formula (I) and (II), compositions comprising compounds of formula (II) and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and MR spectroscopy (MRS).

  本发明涉及一种新的化合物，其化学式为(I)和(II)，包括化合物(II)的组合物以及它们在磁共振成像（MRI）和磁共振波谱（MRS）中作为对比剂的用途。